Melanoma Therapeutics (MCP-6303) - Global Industry Analysts, Inc.

Research Abstract

This report analyzes the worldwide markets for Melanoma Therapeutics in US$ Million. The report provides separate comprehensive analytics for US, and Rest of World. Annual estimates and forecasts are provided for each region for the period 2007 through 2015. Also, a six-year historic analysis is provided for these markets. The report profiles 73 companies including many key and niche players such as Abraxis BioScience, Inc., Astellas Pharma US, Inc., Antigenics Inc., AVAX Technologies, Inc., BioVex, Inc., GenVec, Inc., GlaxoSmithKline Plc., Medarex Inc., Merck KGAA, Oxford Biomedica Plc, Pfizer, Inc., Progen Pharmaceuticals Limited, and Vical Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

Code :	MCP-6303
Price :	$3950
Companies :	73

Pages :	616
Date :	April 2010
Market Data Tables :	176

Complimentary Market Brief:

Request a Complimentary Copy of the Report Insights, Key Findings, Drivers, Trends, Program Sources, and Methodology.

MELANOMA THERAPEUTICS (Complete Report)

Pages : 616

$3950

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

$100

Study Reliability and Reporting Limitations.....I-1

Disclaimers.....I-2

Data Interpretation & Reporting Level.....I-3

Quantitative Techniques & Analytics.....I-3

Product Definitions and Scope of Study.....I-3

II. EXECUTIVE SUMMARY

$2250

1. MARKET OVERVIEW.....II-1

$300

Melanoma Incidence Surging at Significant Rate.....II-1

Current Standard Treatment for Melanoma.....II-1

High Unmet Need, and Challenges Abound.....II-1

$100

Recommencement of Discontinued Trials Provides a Ray a Hope!.....II-2

Cancer Vaccines: Potentially a Future Aid for Melanoma Treatment.....II-2

$100

How Does Cancer Vaccines Works?.....II-3

Whole Cell Vaccines for Melanoma.....II-3

Melanoma Therapeutics Market: Current & Future Analysis.....II-3

$100

2. MELANOMA PIPELINE – AN OVERVIEW.....II-4

$450

Research for Novel Drug Therapies Rampant Worldwide.....II-4

Selected Products and Targets for Melanoma Treatment Under Phase III Clinical Trials

(As of 2008).....II-4

$100

Selected Products and Targets for Melanoma Treatment Under Phase II Clinical Trials

(As of 2008).....II-5

$200

Selected Products and Targets for Melanoma Treatment Under Phase I and Pre-Clinical

Trials (As of 2008).....II-7

$100

Major Drugs Under Investigations for Metastatic Melanoma Treatment (As of

2008).....II-8

What Does the Future Hold for Melanoma in Vaccines Space?.....II-8

Pipeline Analysis of Melanoma Vaccines.....II-8

Select Companies with Melanoma Vaccines under Phase III Clinical Trials.....II-8

$100

Select Companies with Melanoma Vaccines under Phase II Clinical Trials.....II-9

Select Companies with Melanoma Vaccines under Phase I Clinical Trials.....II-9

$100

3. MELANOMA: THE DISEASE AND TREATMENT.....II-10

$850

What is Melanoma?.....II-10

Melanoma of Skin: A Grave form of Skin Cancer.....II-10

Melanoma Vis-à-vis Other Skin Cancers.....II-10

$100

Types of Melanoma.....II-11

Risk Factors for Melanoma.....II-11

Indoor Tanning Devices Hold Potential for Causing Skin Cancer.....II-11

$100

Fair Skinned People: At Greater Risk.....II-12

Prevention of Melanoma.....II-12

How Is Melanoma Detected?.....II-12

Ugly Duckling Sign – A New Approach for Melanoma Detection.....II-12

$100

Diagnosis of Melanoma.....II-13

Skin Biopsy, an Initial Step.....II-13

Fine Needle Aspirate (FNA).....II-13

Shave Biopsy.....II-13

Punch Biopsy.....II-13

Incisional Biopsy.....II-13

Excisional Biopsy.....II-13

Process After Biopsy: A Review.....II-13

$100

Analysis of Lymph Nodes Status, A Second Step.....II-14

Lactate Dehydrogenase Tests for Metastases Melanoma.....II-14

Prognosis of the Disease.....II-14

$100

Melanoma Staging: Crucial for Treatment.....II-15

Melanoma Treatment: An Overview.....II-15

$100

Surgical Excision of Melanoma.....II-16

Sentinel Lymph Node Biopsy.....II-16

Standard Treatment, Post Surgery.....II-16

$100

Surgical Adjuvant Treatment.....II-17

Standard Excision for Lentigo Maligna.....II-17

Surgical Treatment of Metastatic Melanoma.....II-17

$100

Stereotactic Radiosurgery For Brain Metastases Melanoma.....II-18

Chemotherapy for Melanoma.....II-18

Side Effects.....II-18

$100

Chemotherapeutic Regional Perfusion.....II-19

Immunotherapy for Melanoma.....II-19

Biochemotherapy: Chemo Plus Biotherapy.....II-19

$100

Radiation Therapy.....II-20

Vaccine Immunotherapy.....II-20

Other Treatments.....II-20

$100

4. RESEARCH FINDINGS.....II-21

$100

Vitamin D May Prevent Severe Melanoma Lesions.....II-21

Stress Accelerates Growth Of Melanoma Lesions.....II-21

Interaction Between Akt3 and (V600E)B-Raf Proteins in a Mole, Leads to

Melanoma.....II-21

$100

5. RESEARCH & DEVELOPMENT.....II-22

$350

Synta Obtains FDA Approval to Resume Development of Elesclomol.....II-22

Nexavar Fails in Late Stage Melanoma Trial.....II-22

Biovex Commences Phase III Clinical Trial of Oncovexgm-CSF.....II-22

Medarex and Bristol Myers Squibb Announces Enhanced Survival Rate through

Ipilimumab.....II-22

$100

A Pain-Less Melanoma Test, Under Evaluation.....II-23

Encouraging Phase III Clinical Trials of a Melanoma Vaccine.....II-23

Plexxikon Announces Phase I Results of PLX4032".....II-23

$100

Provectus Treats Metastatic Melanoma Patients Under Phase II Clinical Study with

PV-10.....II-24

GENOMEL Project Investigates Environmental/ Genetic Risk Factors for Melanoma.....II-24

$100

Antigenics Announces Results of a Phase III Trial of Oncophage (vitespen)

Vaccine.....II-25

CuraGen Advances Phase II Clinical Trial of "CR011-vcMMAE".....II-25

Inovio Evaluates a Combination of Plasmid IL-12 and Electroporation Technology for the

Treatment of Metastatic Melanoma.....II-25

$200

6. RECENT INDUSTRY ACTIVITY.....II-27

$700

Pfizer Collaborates with Debiopharm.....II-27

PharmaSynth Licenses Muparfostat to Global TransBiotech.....II-27

Celldex Therapeutics Acquires CuraGen.....II-27

$100

Bristol-Myers Squibb Acquires Medarex.....II-28

Cephalon Acquires Outstanding Shares of Arana Therapeutics.....II-28

$100

ImmunoVaccine Technologies Inks Agreement with Scancell.....II-29

Vical Inks Agreement with Abic for Allovectin-7 Immunotherapeutic.....II-29

Immunomedics Collaborates with Alexis Biotech.....II-29

$100

NeoGenomics Signs Strategic Supply Deal with Abbott.....II-30

ErgoMed Collaborates with Genzyme.....II-30

PDS Biotechnology and Merck Eprova Sign CLA.....II-30

$100

FDA Oncologic Drug Advisory Committee Recommends for Approval, PEGINTRON® for Melanoma

Treatment.....II-31

Takeda Acquires IDM Pharma.....II-31

Abraxis BioScience Receives FDA’s Orphan Drug Status for Abraxane.....II-31

$100

Progen Pharmaceuticals Spins-Off its Manufacturing Business.....II-32

Eli Lilly and Company Acquires SGX Pharmaceuticals.....II-32

GlaxoSmithKline and Synta Pharmaceutical Obtains the Orphan Drug Status from the US

FDA, for Elesclomol.....II-32

Vical Inks Binding LOI with EIP.....II-32

$100

GammaCan Signs Supply Deal with Bio Products Laboratory.....II-33

Medarex and Bristol Myers Squibb Delays Submission of BLA, for Ipilimumab.....II-33

$100

Pfizer Discontinues Phase 3 Clinical Trials of Tremelimumab, in Advanced Melanoma

Patients.....II-34

Alnylam Pharmaceuticals Collaborates with University of California to Evaluate an RNAi

Therapeutic for Metastatic Uveal Melanoma Treatment.....II-34

GenVec and Cobra Ink Manufacturing Agreement.....II-34

$100

SciClone Pharmaceuticals Sings a Deal with FDA for Thymalfasin.....II-35

Abraxis BioScience, NCCN, and AstraZeneca Collaborates For Assessment of Abraxane, the

Anti-Cancer Drug.....II-35

$100

Oxford BioMedica Acquires Oxxon Therapeutics.....II-36

$100

7. FOCUS ON SELECT GLOBAL PLAYERS.....II-37

$450

Abraxis BioScience, Inc. (USA).....II-37

Astellas Pharma US, Inc. (USA).....II-37

Antigenics Inc. (USA).....II-37

$100

AVAX Technologies, Inc. (USA).....II-38

BioVex, Inc. (USA).....II-38

$100

GenVec, Inc. (USA).....II-39

GlaxoSmithKline Plc. (UK).....II-39

$100

Medarex Inc. (USA).....II-40

Merck KGAA (Germany).....II-40

Oxford Biomedica Plc. (UK).....II-40

$100

Pfizer, Inc. (USA).....II-41

Progen Pharmaceuticals Limited (Australia).....II-41

$100

Vical Inc. (USA).....II-42

$100

8. GLOBAL MARKET PERSPECTIVE.....II-43

Table 1: World Recent Past, Current & Future Analysis for Melanoma Therapeutics Market by Geographic Region – US, and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2007 through 2015 (includes corresponding Graph/Chart).....II-43

$300

Table 2: World Historic Review for Melanoma Therapeutics Market by Geographic Region – US, and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2001 through 2006 (includes corresponding Graph/Chart).....II-44

Table 3: World 13-Year Perspective for Melanoma Therapeutics Market by Geographic Region - Percentage Breakdown of Sales for the US, and Rest of World Markets for the Years 2003, 2009 & 2015.....II-44

$300

III. MARKET

$1950

1. THE UNITED STATES.....III-1

$1025

A. Market Analysis.....III-1

Increasing Incidence of Melanoma Fuels Growth.....III-1

Table 4: Melanoma Incidence in the US by Gender: 2008.....III-1

Table 5: Cancer Incidence in Males by Cancer Type: Percentage Share Breakdown in 2008 (includes corresponding Graph/Chart).....III-1

$150

Table 6: Cancer Incidence in Females by Cancer Type: Percentage Share Breakdown in 2008 (includes corresponding Graph/Chart).....III-2

Surging Mortality, Demands Novel Therapeutics for Melanoma.....III-2

Table 7: Melanoma Mortality in the US by Gender: 2005 & 2008 (includes corresponding Graph/Chart).....III-2

$150

Table 8: Five-Year Survival Rate for Patients with Melanoma of Skin in the US (1996-2003): Percentage Share Breakdown by Diagnosis Stage (includes corresponding Graph/Chart).....III-3

Fair-Skinned and Light Hair Whites at High RisK.....III-3

Table 9: Five-Year Survival Rate for Patients with Melanoma of Skin in the US (1996-2003): Percentage Share Breakdown by Race (includes corresponding Graph/Chart).....III-3

$150

US Melanoma Fact Sheet: A Recapitulation.....III-4

Major Players.....III-4

$300

Strategic Corporate Developments.....III-8

$525

B. Market Analytics.....III-15

Table 10: US Recent Past, Current & Future Analysis for Melanoma Therapeutics Market with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-15

Table 11: US Historic Review for Melanoma Therapeutics Market with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-15

$150

2. REST OF WORLD.....III-16

$975

A. Market Analysis.....III-16

Select Regional Markets Under Review.....III-16

Australia.....III-16

World’s Leading Region with Highest Skin Cancer Incidence.....III-16

Table 12: Melanoma Incidence Rate in Australia by Age Group: 2008 (2008) (includes corresponding Graph/Chart).....III-16

Table 13: Melanoma Incidence Rate in Australian Males by Age Group: 2008 (includes corresponding Graph/Chart).....III-16

$150

Table 14: Melanoma Incidence Rate in Australian Females by Age Group: 2008 (includes corresponding Graph/Chart).....III-17

Other Key Facts on Melanoma Incidence in Australia.....III-17

The United Kingdom.....III-17

Young Women in UK Becoming Increasing Victims of Melanoma.....III-17

$150

Table 15: Newly Diagnosed Cases of Melanoma of Skin in the UK (2003-2005): Breakdown by Select Regions, and Gender (includes corresponding Graph/Chart).....III-18

Table 16: Mortality Due to Melanoma of Skin in the UK (2003-2005): Breakdown by Select Regions, and Gender (includes corresponding Graph/Chart).....III-18

Major Players.....III-18

$300

Strategic Corporate Developments.....III-20

$300

B. Market Analytics.....III-24

Table 17: Rest of World Recent Past, Current & Future Analysis for Melanoma Therapeutics Market with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-24

$150

Table 18: Rest of World Historic Review for Melanoma Therapeutics Market with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-25

$150

IV. COMPETITIVE LANDSCAPE

532

$995

Total Companies Profiled: 73 (including Divisions/Subsidiaries - 80)
Region/Country                 Players

The United States                 59
Canada                             2
Japan                              1
Europe                            13 
     France                        1
     Germany                       5
     The United Kingdom            4
     Rest of Europe                3
Asia-Pacific (Excluding Japan)     3
Middle East                        2

Click here to request a full table of contents and more details on this project.

MELANOMA THERAPEUTICS - A GLOBAL STRATEGIC BUSINESS REPORT

Research Abstract

Complimentary Market Brief:

TABLE OF CONTENTS

MELANOMA THERAPEUTICS - A GLOBAL STRATEGIC BUSINESS REPORT stLight.options({ publisher:'12345' });

Research Abstract

Complimentary Market Brief:

TABLE OF CONTENTS

MELANOMA THERAPEUTICS - A GLOBAL STRATEGIC BUSINESS REPORT